• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP

Cal­i­for­nia up­start Xyphos wants to tack­le CAR-T's big prob­lems

8 years ago
Startups
Discovery

As­traZeneca’s asth­ma drug tralok­inum­ab goes 0 for 3 in PhI­II as 2 more tri­als flop

8 years ago
R&D

Fra­zier boosts next pure-play biotech fund to $419M, read­ies new bets for a prac­ticed strat­e­gy

8 years ago
Financing

Greek health min­is­ter takes is­sue with Roche's with­draw­al of can­cer med­i­cine due to manda­to­ry, retroac­tive dis­count

8 years ago
Pharma

Neos con­sid­er­ing of­fers af­ter re­ject­ing PDL’s $300M bid: Reuters

8 years ago
Deals

As­traZeneca gets an ear­ly green light on BTK block­buster hope­ful Calquence

8 years ago
Pharma

Ex­pand­ing its pre­clin­i­cal at­tack on Duchenne MD, Sarep­ta grabs a li­cense for Duke's CRISPR tech

8 years ago
Discovery

Re­gen­eron, Sanofi rack up a PhI­II asth­ma win for dupilum­ab; Ve­rastem preps FDA app for du­velis­ib

8 years ago
News Briefing

Stem­line wraps pos­i­tive piv­otal tri­al for its con­tro­ver­sial lead can­cer drug, clear­ing a path to the FDA

8 years ago
R&D

No­var­tis hus­tles along an­oth­er FDA ap­pli­ca­tion for CAR-T star, tack­ling Gilead head on

8 years ago
R&D

PhI­II deal­mak­ing fren­zy in i/o con­tin­ues as As­traZeneca fol­lows PA­CIF­IC with a new In­cyte IDO1 com­bo

8 years ago
R&D

Bris­tol-My­ers, J&J sink cash in­to a new $95M Eu­ro­pean biotech fund

8 years ago
Financing

Grail CSO Vikram Ba­jaj jumps to VC firm Fore­site, takes lead on per­son­al­ized meds

8 years ago
People
Financing

Sanofi Gen­zyme re­treats from its Parkin­son’s deal with gene ther­a­py up­start Voy­ager, part of an $845M pact

8 years ago
Pharma
Cell/Gene Tx

Can tiny Mus­tang Bio com­pete on the CAR-T front with gi­ants like No­var­tis and Gilead? Man­ny Litch­man aims to find out

8 years ago
Pharma

Blood­ied Cel­gene posts promis­ing ozan­i­mod PhI­II MS da­ta, but is it re­al­ly a $6 bil­lion drug?

8 years ago
R&D

In­sid­ers: The top 20 rare dis­ease spe­cial­ists spot­light key biotech trends be­hind the boom

8 years ago

Vaxart re­verse merges its way on­to Nas­daq, climb­ing aboard the Avi­ra­gen shell

8 years ago
Deals

In a strate­gic switch, Sum­it­o­mo Dainip­pon bags rights to a PhI­II di­a­betes drug from Pox­el in $300M deal

8 years ago
Pharma

At­las-in­cu­bat­ed Kymera leaps out of stealth mode, joins the hunt for game-chang­ing pro­tein degra­da­tion drugs

8 years ago
Financing
Startups

Mereo bags rights to the lat­est As­traZeneca castoff, shifts fo­cus; Neos re­jects buy­out of­fer

8 years ago
News Briefing
Pharma

No­var­tis builds can­cer pipeline with a new plat­form/drug buy­out, bag­ging Ad­vanced Ac­cel­er­a­tor Ap­pli­ca­tions for $3.9B

8 years ago
Deals

Mer­ck’s bad day: $310M for Not­Petya, fran­chise drugs take a hit and now the EMA push­es back on Keytru­da

8 years ago
Pharma

Toca­gen stream­lines piv­otal plans; Wave Life Sci­ences cuts rib­bon on new man­u­fac­tur­ing plant

8 years ago
News Briefing
First page Previous page 1073107410751076107710781079 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times
Endpoints News

Log in to your account

email

password

Endpoints News

request login link

Enter the email associated to with your Endpoints account, and we'll send you a one-time login link (no password needed). The link expires after 24 hours.

email

Endpoints News

reset password

Enter the email associated to with your Endpoints account, and we'll send you a link to reset your password. The link expires after 24 hours and can only be used once.

email

Endpoints News

Sign up for free to read a limited number of articles each month.

About You

Newsletter Interests

Pick what newsletters get delivered to your inbox each week.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 3:30 PM ET

BREAKING NEWS ALERTS 2-3 times a week

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET

POST-HOC 1-2 times a week

Healthcare

ENDPOINTS HEALTH TECH Tuesday, Thursday at 10 AM ET

BREAKING NEWS ALERTS 2-3 times a week

Want unlimited access? Sign up for a premium subscription plan.